International Research Journal of Oncology

Spatial transcriptomics and related spatially resolved profiling technologies have transformed the characterization of tumor microenvironment architecture, revealing spatial patterns of cellular organization that are tightly linked to cancer behavior. However, despite their biological insights, spatial-omics approaches have had limited impact on routine cancer diagnostics, reflecting a translational gap between high-dimensional discovery and clinical implementation. In this work, we introduce a compression-to-clinic framework, defined as a systematic strategy for distilling complex spatial-omics data into minimal, information-efficient biomarker panels that retain diagnostic signal while remaining compatible with routine pathology workflows. We synthesize evidence showing that diagnostically relevant information is concentrated within a limited set of spatial features, including tumor–immune interfaces, stromal organization, and immune cell positioning. Through biologically informed feature reduction, these spatial signatures can be translated into clinic-ready assays using established platforms such as immunohistochemistry and RNA in situ hybridization on formalin-fixed, paraffin-embedded tissue. We further address key implementation considerations, including assay feasibility, reproducibility, cost, validation, and regulatory alignment. Focusing on clinically challenging scenarios such as indeterminate lesions, early-stage disease, and inflammation-associated cancers we illustrate how compressed spatial biomarker panels can augment standard histopathology and improve diagnostic decision-making. Collectively, this framework provides a practical roadmap for overcoming the translational bottleneck in spatial-omics and for converting tumor microenvironment architecture into actionable cancer diagnostics.